Dr. Peter O'Dwyer, MD

• Medical Oncology

• Internal Medicine

• Pediatrics

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Dublin / Trinity College / School Of Physic

  Medical School

• Association between VEGF splice isoforms and progression free survival in metastatic colorectal cancer patients treated with bevacizumab, 2012-10-25

• Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E4203), 2017-12-06

• Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors, 2010-04-13

• Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials, 2023-03-16

• Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma, 2018-12-26

• Combined BRAF, EGFR, and MEK Inhibition in Patients WithBRAFV600E-Mutant Colorectal Cancer, 2018-02-05

• A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, 2013-08-27

• National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), 2023-04-14

• First-in-Human Phase 1 Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients With Advanced Solid Malignancies, 2017-01-04

• Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination Withnab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer, 2019-11-26

• Pharmacokinetic Analysis of Irinotecan Plus Bevacizumab in Patients with Advanced Solid Tumors, 2009-05-05

• BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer, 2020-02-11

• Differential Outcomes in Codon 12/13 and Codon 61NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients withNRAS-Mutated Tumors, 2021-02-26

• Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germlineBRCA1, BRCA2orPALB2mutation, 2019-12-02

• Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma, 2019-12-20

• A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors, 2020-12-17

• A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence, 2022-12-03

• JNK1 INHIBITION ATTENUATES HYPOXIA-INDUCED AUTOPHAGY AND SENSITIZES TO CHEMOTHERAPY, 2016-05-23

• Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131), 2020-01-10

• Early treatment-related neutropenia predicts response to palbociclib, 2020-07-09

• Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours, 2019-09-12

• DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models, 2022-08-20